BioAtla, Inc.

Hello and welcome to the BioAlta second quarter 2022 earnings call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your touchtone phone. To withdraw your question, please press star then two. Please note, today's event is being recorded. I now would like to turn the conference over to your host today, Bruce Mackel. Bruce Mackel, please go ahead.

Thank you, Operator, and good afternoon, everyone. With me today on the phone from BioAtla are Dr. Jay Short, Chairman, CEO, and Co-Founder, Scott Smith, President, Philippe Martin, Chief of Clinical Development and Operations, Sherry Lydick, Senior Vice President, Commercial Strategy, and Richard Waldron, Chief Financial Officer. Earlier this afternoon, BioAtla released financial results and a business update for the quarter ended June 30, 2022. A copy of the press release is available on the company's website. Before we begin, I'd like to remind everyone that statements made during this conference call will include forward-looking statements, including but not limited to statements regarding BioAtla's business plans and prospects, financial and operating performance and expectations, operating costs and expenses, product pipeline, clinical trial and regulatory timing and associated resource requirements, its programs and potential partnerships, and the advancement of its CAB technology and product candidates. These statements are subject to various risks, assumptions, and uncertainties, that can cause actual results to differ materially and are described in the filings made with the SEC, including the most recent quarterly report on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today, August 9, 2022, and BioATLA disclaims any obligation to update such statements to reflect future information, events, or circumstances except as required by law. With that, I'd like to turn the call over to Jay Short. Jay?

Thank you, Bruce. Thanks to everyone for joining us for our second quarter 2022 BioAtlas earnings call. The broad applicability of BioAtlas CAP technology has allowed us to continue advancing the development of our innovative clinical and preclinical programs. The second quarter was marked by strong execution with promising results across five potentially registration-enabling ongoing phase two trials for our two latest stage CAB-ADC product candidates, Mecbotimab-vidotin, or BA3011, and Ozu-Riftimab-vidotin, or BA3021, across multiple solid tumor types for these first-in-class therapeutic candidates. But before I go any further, I'd like to remind everyone that additional details related to what we are going to present are available on our website as part of our updated company presentation that may be helpful to you. We have several additional upcoming catalysts this year for both our lead assets, including important results to be covered in today's discussion. We previously shared interim data on our BA3011 Phase II sarcoma study, And we now look forward to enrolling multiple sarcoma subtypes into part two of that study. Further, on today's call, we will discuss new results for additional sarcoma subtypes and important initial interim data for the non-small cell lung cancer study for BA3011. BA3021 studies also continue to advance, and we anticipate an interim update for non-small cell lung cancer in the fourth quarter. We also expect that our successful validation of the liquid biopsy will accelerate the melanoma study for an enrollment update later this year. In addition, we are actively screening in our head and neck study with the first patient anticipated to be dosed shortly. Our Phase I-II basket trial for our CAB CTLA-4 antibody, BA3071, is currently ongoing with the first patient dose completed. We also remain on track for our pre-IND meeting and IND filing for our dual-cAB bispecific antibody, EPCAM CD3, or BA3182, this year. We are pleased with our cumulative results that continue to support both the efficacy and safety from our differentiated proprietary CAB platform thus far in 2022, and I believe we are well-positioned to continue with strong execution. Most importantly, we are excited to share the updates of our ongoing clinical programs with you today, in particular, observations from our Phase II non-small cell lung cancer study with our lead asset, BA3011. With that, I would now like to turn the call over to Philippe for additional details. Philippe?